Clinical and neurological manifestations of COVID-19 and other coronavirus infections: A literature review

As is known, the issues of pathogenesis, diagnosis and treatment of the new coronavirus infection COVID-19 are the most priority areas of scientific research in the modern clinic of internal diseases. The rate of emergence of new scientific data in the leading libraries PubMed, Medline, Cochrane Library and eLibrary, which can potentially be important in the correction of ongoing therapy for infection and its complications, is extremely high. In turn, this dictates the need for a comprehensive discussion of the results of newly published studies. These issues include clinical and neurological manifestations of COVID-19 and other coronavirus infections. The exact mechanism by which the SARS-CoV-2 virus enters the structures of the central nervous system is unknown. Thus, two pathways for the penetration of the COVID-19 pathogen are most actively discussed: the hematogenous pathway (through the systemic circulation into the vessels of the brain with a low linear blood flow velocity, which allows the virus to adhere to the surface of the endothelium and penetrate into the nervous tissue through damage to the latter) and the contact pathway (through the cribriform plate and the olfactory bulb). It should also be noted that a number of experimental works clearly demonstrate the pathogenic effect of other members of the Coronaviridae family on the neurons of the respiratory and vasomotor centers. The review presents an analysis of current literature data on the study of clinical and neurological manifestations of COVID-19 and other coronavirus infections. It is important to emphasize that patients with a severe course of COVID-19 deserve special attention, requiring observation in the intensive care unit in order to prevent the development of fatal neurological complications.

1. Arutyunov GP, Koziolova NA, Tarlovskaya EI, Arutyunov AG, Grigorjeva NYu, Dzhunusbekova GA, et al. The agreed experts’ position of the Eurasian Association of Therapists on some new mechanisms of COVID- 19 pathways: Focus on hemostasis, hemotransfusion issues and blood gas exchange. Kardiologiia. 2020; 60(5): 9-19. (In Russ.). doi: 10.18087/cardio.2020.5.n1132

2. Kolobukhina LV, Burgasova OA, Kraeva LA, Gushchin VA, Burtseva EI, Kruzhkova IS, et al. Clinical and laboratory profile of patients with COVID-19 admitted to hospital in Moscow between May and July 2020. Infectious Diseases. 2021; 19(2): 5-15. (In Russ.). doi: 10.20953/1729-9225-2021-2-5-15

3. Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: A systematic review. J Neurol Scie. 2020; 413: 116832. doi: 10.1016/j.jns.2020.116832

4. Satarker S, Nampoothiri M. Involvement of the nervous system in COVID-19: The bell should toll in the brain. Life Scie. 2020; 262: 118568. doi: 10.1016/j.lfs.2020.118568

5. Bobker SM, Robbins MS. COVID-19 and headache: A primer for trainees. Headache. 2020; 60(8): 1806-1811. doi: 10.1111/head.13884

6. Walls AC, Fiala B, Schäfer A, Wrenn S, Pham MN, Murphy M, et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell. 2020; 183(5): 1367-1382.e17. doi: 10.1016/j.cell.2020.10.043

7. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020; 109: 102433. doi: 10.1016/j.jaut.2020.102433

8. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020; 94(7): e00127-20. doi: 10.1128/JVI.00127-20

9. Doobay MF, Talman LS, Obr TD, Tian X, Davisson RL, Lazartigues E. Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol. 2007; 292(1): R373-R381. doi: 10.1152/ajpregu.00292.2006

10. Palasca O, Santos A, Stolte C, Gorodkin J, Jensen LJ. TISSUES 2.0: An integrative web resource on mammalian tissue expression. Database (Oxford). 2018; 2018: bay028. doi: 10.1093/database/bay028

11. McCray PB Jr, Pewe L, Wohlford-Lenane C, Hickey M, Manzel L, Shi L, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol. 2007; 81(2): 813-821. doi: 10.1128/JVI.02012-06

12. Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K. Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review. Clin Neurol Neurosurg. 2020; 194: 105921. doi: 10.1016/j.clineuro.2020.105921

13. Divani AA, Andalib S, Biller J, Di Napoli M, Moghimi N, Rubinos CA, et al. Central nervous system manifestations associated with COVID-19. Curr Neurol Neurosci Rep. 2020; 20(12): 60. doi: 10.1007/s11910-020-01079-7

14. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: Tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. 2020; 11(7): 995-998. doi: 10.1021/acschemneuro.0c00122

15. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020; 92(6): 552-555. doi: 10.1002/jmv.25728

16. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020; 77(6): 683-690. doi: 10.1001/jamaneurol.2020.1127

17. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497-506. doi: 10.1016/S0140-6736(20)30183-5

18. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020; 395(10223): 507-513. doi: 10.1016/S0140-6736(20)30211-7

19. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: Retrospective case series. BMJ. 2020; 368: m606. doi: 10.1136/bmj.m606

20. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061-1069. doi: 10.1001/jama.2020.1585

21. Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, et al. Characteristics of COVID-19 infection in Beijing. J Infect. 2020; 80(4): 401-406. doi: 10.1016/j.jinf.2020.02.018

22. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al.; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382(18): 1708-1720. doi: 10.1056/NEJMoa2002032

23. Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, Sánchez-Larsen Á, Layos-Romero A, García-García J, et al. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. Neurology. 2020; 95(8): e1060-e1070. doi: 10.1212/WNL.0000000000009937

24. Belvis R. Headaches during COVID-19: My clinical case and review of the literature. Headache. 2020: 60(7): 1422-1426. doi: 10.1111/head.13841

25. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020; 8(4): e21. doi: 10.1016/S2213-2600(20)30116-8

26. Maassen Van Den Brink A, de Vries T, Danser AHJ. Headache medication and the COVID-19 pandemic. J Headache Pain. 2020; 21(1): 38. doi: 10.1186/s10194-020-01106-5

27. Rinott E, Kozer E, Shapira Y, Bar-Haim A, Youngster I. Ibuprofen use and clinical outcomes in COVID-19 patients. Clin Microbiol Infect. 2020; 26(9): 1259.e5-1259.e7. doi: 10.1016/j.cmi.2020.06.003

28. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ. 2020; 368: m1091. doi: 10.1136/bmj.m1091

29. Alkeridy WA, Almaghlouth I, Alrashed R, Alayed K, Binkhamis K, Alsharidi A, et al. A unique presentation of delirium in a patient with otherwise asymptomatic COVID-19. J Am Geriatr Soc. 2020; 68(7): 1382-1384. doi: 10.1111/jgs.16536

30. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020; 382: 2268-2270. doi: 10. 1056/NEJMc2008597

31. Kotfis K, Williams Roberson S, Wilson JE, Dabrowski W, Pun BT, Ely EW. COVID-19: ICU delirium management during SARS-CoV-2 pandemic. Crit Care. 2020; 24(1): 176. doi: 10.1186/s13054-020-02882-x

32. Cooper KW, Brann DH, Farruggia MC, Bhutani S, Pellegrino R, Tsukahara T, et al. COVID-19 and the chemical senses: Supporting players take center stage. Neuron. 2020; 107(2): 219-233. doi: 10.1016/j.neuron.2020.06.032

33. Galougahi MK, Ghorbani J, Bakhshayeshkaram M, Naeini AS, Haseli S. Olfactory bulb magnetic resonance imaging in SARS- CoV-2-induced anosmia: The first report. Acad Radiol. 2020; 27(6): 892-893. doi: 10.1016/j.acra.2020.04.002

34. Parma V, Ohla K, Veldhuizen MG, Niv MY, Kelly CE, Bakke AJ, et al. More than smell – COVID-19 is associated with severe impairment of smell, taste, and chemesthesis. Chem Senses. 2020; 45(7): 609-622. doi: 10.1093/chemse/bjaa041

35. Kaye R, Chang CWD, Kazahaya K, Brereton J, Denneny JC 3rd. COVID-19 anosmia reporting tool: Initial findings. Otolaryngol Head Neck Surg. 2020; 163(1): 132-134. doi: 10.1177/0194599820922992

36. Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, et al. Self-reported olfactory and taste disorders in SARSCoV-2 patients: A cross-sectional study. Clin Infect Dis. 2020; 71(15): 889-890. doi: 10.1093/cid/ciaa330

37. Menni C, Valdes A, Freydin MB, Ganesh S, El-Sayed Moustafa J, Visconti A, et al. Loss of smell and taste in combination with other symptoms is a strong predictor of COVID-19 infection. medRxiv. 2020; 2020.04.05.20048421. doi: 10.1101/2020.04.05.20048421

38. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): A multicenter European study. Eur Arch Otorhinolaryngol. 2020; 277(8): 2251-2261. doi: 10. 1007/s00405-020-05965-1

39. Song J, Deng Y-K, Wang H, Wang Z-C, Liao B, Ma J, et al. Self-reported taste and smell disorders in patients with COVID-19: Distinct features in China. medRxiv. 2020: 41(1): 14-23. doi: 10.1007/s11596-021-2312-7

40. Avula A, Nalleballe K, Narula N, Sapozhnikov S, Dandu V, Toom S, et al. COVID-19 presenting as stroke. Brain Behav Immun. 2020; 87: 115-119. doi: 10.1016/j.bbi.2020.04.077

41. Karimi N, Sharifi Razavi A, Rouhani N. Frequent convulsive seizures in an adult patient with COVID-19: A case report. Iran Red Crescent Med J. 2020; 22(3): e102828. doi: 10.5812/ircmj.102828

42. Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020; 94: 55-58. doi: 10.1016/j.ijid.2020.03.062

43. Lu L, Xiong W, Liu D, Liu J, Yang D, Li N, et al. New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: A retrospective multicenter study. Epilepsia. 2020; 61(6): 49-53. doi: 10.1111/epi.16524

44. Yazbeck M, Sra P, Parvizi J. Rapid response electroencephalography for urgent evaluation of patients in community hospital intensive care practice. J Neurosci Nurs. 2019; 51(6): 308-312. doi: 10.1097/jnn.0000000000000476

45. Hepburn M, Mullaguri N, George P, Hantus S, Punia V, Bhimraj A, et al. Acute symptomatic seizures in critically ill patients with COVID-19: Is there an association? Neurocrit Care. 2021; 34(1): 139-143. doi: 10.1007/s12028-020-01006-1

46. Vollono C, Rollo E, Romozzi M, Frisullo G, Servidei S, Borghetti A, et al. Focal status epilepticus as unique clinical feature of COVID-19: A case report. Seizure. 2020; 78: 109-112. doi: 10.1016/j.seizure.2020.04.009

47. Louis S, Dhawan A, Newey C, Nair D, Jehi L, Hantus S, et al. Continuous electroencephalography (cEEG) characteristics and acute symptomatic seizures in COVID-19 patients. medRxiv. 2020; 131(11): 2651-2656. doi: 10.1101/2020.05. 26.20114033

48. Galanopoulou AS, Ferastraoaru V, Correa DJ, Cherian K, Duberstein S, Gursky J, et al. EEG findings in acutely ill patients investigated for SARS-CoV-2/COVID-19: A small case series preliminary report. Epilepsia Open. 2020; 5(2): 314-324. doi: 10.1002/epi4.12399

49. Morfopoulou S, Brown JR, Davies EG, Anderson G, Virasami A, Qasim W, et al. Human coronavirus OC43 associated with fatal encephalitis. N Engl J Med. 2016; 375(5): 497-498. doi: 10.1056/NEJMc1509458

50. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology. 2020; 201187: 119-120. doi: 10.1148/radiol.2020201187

51. Shcherbak SG, Vologzhanin DA, Kamilova TA, Golota AS. Acute cerebrovascular accident in COVID-19. University Therapeutic Journal. 2023; 5(1): 5-35. (In Russ.).

52. Quintanilla-Sánchez C, Salcido-Montenegro A, González-González JG, Rodríguez-Gutiérrez R. Acute cerebrovascular events in severe and nonsevere COVID-19 patients: A systematic review and meta-analysis. Rev Neurosci. 2022; 33(6): 631-639. doi: 10.1515/revneuro-2021-0130

53. Chukhlovina ML. Polyneuropathies during COVID-19 epidemics. S.S. Korsakov Journal of Neurology and Psychiatry. 2021; 121(5): 138‑143. (In Russ.). doi: 10.17116/jnevro2021121051138

54. Leonhard SE. Diagnosis and management of Guillain – Barré syndrome in ten steps. Nat Rev Neurol. 2019; 15(11): 671-683. doi: 10.1038/s41582-019-0250-9